McEwen Swings to Q4 Earnings-March 2024-www.financetom.com

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

McEwen Swings to Q4 Earnings

Mar 12, 2026 3:37 AM

06:23 AM EDT, 03/12/2026 (MT Newswires) -- McEwen (MUX) reported Q4 net income Thursday of $0.70 per share, swinging from a net loss of $0.16 a year earlier.

Four analysts polled by FactSet expected $0.18.

Revenue for the quarter ended Dec. 31 was $64.6 million.

Three analysts surveyed by FactSet expected $72.8 million.

Previous page： PDS Biotechnology Q3 net loss narrows on lower operating expenses Next page： Suburban Propane Q4 net loss narrows on higher demand, margin management

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

PDS Biotechnology Q3 net loss narrows on lower operating expenses

Nov 13, 2025

Overview * PDS Biotechnology ( PDSB ) Q3 net loss decreases to $9 mln due to lower operating expenses * Adjusted EPS for Q3 beats analyst expectations * Company plans expedited approval for VERSATILE-003 Phase 3 trial Outlook * PDS Biotech plans to seek accelerated approval for VERSATILE-003 Phase 3 trial * Company proposes amendment to use PFS as surrogate...

Suburban Propane Q4 net loss narrows on higher demand, margin management

Nov 13, 2025

Overview * Suburban Propane ( SPH ) Q4 net loss narrows to $35.1 mln from $44.6 mln last year * Adjusted EBITDA for Q4 slightly down from last year * Retail propane gallons sold in Q4 increased 1.8% yr/yr Outlook * Company did not provide specific guidance for future periods Result Drivers * INCREASED PROPANE DEMAND - Strong propane demand...

Clinic operator NeuPath's Q3 revenue beats on fluoroscopy demand

Nov 13, 2025

Overview * NeuPath Q3 revenue rises 26% yr/yr, beating analyst expectations * Adjusted EBITDA for Q3 up 98% yr/yr, marking 27th consecutive positive quarter * Company attributes growth to optimized clinic footprint and increased patient treatment time Outlook * NeuPath expects continued organic and inorganic growth for the balance of 2025 and beyond * Company anticipates strong demand for Arthrosamid...

Fuel cell maker Ballard Power Q3 revenue beats estimates on higher deliveries

Nov 13, 2025

Overview * Ballard Q3 2025 revenue up 120% YoY to $32.5 mln, beating analyst expectations * Gross margin improved to 15%, a 71-point increase YoY * Company reduced operating expenses by 36% due to restructuring Outlook * Company revises 2025 capital expenditure guidance to $8-$12 mln from $15-$25 mln * Ballard expects 2025 operating expenses to be below lower end...